Search

Displaying results 5371 - 5380 of 10000 in total
  1. Drug

    Aminobenzoic acid

    go.drugbank.com/drugs/DB02362
    ApprovedWithdrawn

    It used to be common in sunscreening agents until found to also be a sensitizer. The potassium salt is used therapeutically in fibrotic skin disorders.

  2. Drug

    Asvasiran

    go.drugbank.com/drugs/DB05638
    Investigational

    Asvasiran is an siRNA that targets the respiratory syncytial virus (RSV) N gene and inhibits viral replication. It has the potential to treat or prevent RSV infection.

  3. Drug

    Becatecarin

    go.drugbank.com/drugs/DB06362
    Investigational

    Becatecarin is a derivative of [rebeccamycin].

  4. Drug

    IRX-2

    go.drugbank.com/drugs/DB05643
    Investigational

    It is being investigated to promote or enhance an anti-cancer immune response.

  5. Drug

    Enlicitide

    go.drugbank.com/drugs/DB22580
    ApprovedInvestigational

    (CORALreef Lipids), and by 59% in patients with HeFH (CORALreef HeFH), with comparable reductions in non-HDL-C and apolipoprotein B. … [L63795] Enlicitide is indicated as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH), and was studied in

  6. Drug

    AZD3409

    go.drugbank.com/drugs/DB04893
    Experimental

    AZD3409 is a farnesyl-transferase inhibitor (FAR) indicated for the treatment of solid tumors. Phase I trials were initiated January 2003, and were ongoing as of February 2004.

  7. Drug

    Cemivameran

    go.drugbank.com/drugs/DB19415
    Approved

    It is the active ingredient in the 2024-2025 formulation of Pfizer-BioNTech's Comirnaty vaccine.[L36030] … Cemivameran (BNT162b2 Omicron (KP.2)) is COVID-19 mRNA vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Omicron variant lineage KP.2.

  8. Drug

    MBX-2044

    go.drugbank.com/drugs/DB05598
    Investigational

    MBX-2044 was under investigation in clinical trial NCT00422487 (Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes).

  9. Drug

    Veltuzumab

    go.drugbank.com/drugs/DB05656
    Investigational

    Veltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin's lymphoma.

  10. Drug

    Mesmulogene ancovacivec

    go.drugbank.com/drugs/DB06584
    Investigational

    with MVA-MUC1-IL2 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) responses against tumor cells expressing MUC1, a tumor associated antigen, resulting in … Expression of IL-2 augments the specific CTL response against MUC1 expressing cells. [L5191]